TENAX THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
TENAX THERAPEUTICS, INC. (TENX) reported Increase (Decrease) in Accounts Payable of $754.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $449.00K.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $305.00K.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $432.00K, a 72.57% decline year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $5.05M, a 612.85% increase year-over-year.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was $2.88M, a 171.56% increase from fiscal 2024.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $1.06M, a 35.71% decline from fiscal 2023.
- TENAX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $1.65M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $449.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $754.00K 10-Q · filed 2026-07-31 | $1.19M derived: sum of 3 quarters · filed 2026-07-31 | $6.23M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $305.00K 10-Q · filed 2026-05-12 | $737.00K derived: sum of 2 quarters · filed 2026-05-12 | $5.78M derived: sum of 3 quarters · filed 2026-05-12 | $4.51M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $5.48M derived: sum of 2 quarters · filed 2026-03-10 | $4.20M derived: sum of 3 quarters · filed 2026-07-31 | $2.88M 10-K · filed 2026-03-10 |
| 2025-09-30 | $5.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.77M derived: sum of 2 quarters · filed 2026-07-31 | $2.45M 10-Q · filed 2025-11-12 | $4.03M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$2.60M 10-Q · filed 2026-07-31 | -$1.02M derived: sum of 3 quarters · filed 2026-07-31 | -$312.00K derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | -$1.32M 10-Q · filed 2026-05-12 | $257.00K derived: sum of 2 quarters · filed 2026-05-12 | $965.00K derived: sum of 3 quarters · filed 2026-05-12 | $744.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.28M derived: sum of 2 quarters · filed 2026-03-10 | $2.06M derived: sum of 3 quarters · filed 2026-03-10 | $1.06M 10-K · filed 2026-03-10 |
| 2024-09-30 | $708.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $487.00K derived: sum of 2 quarters · filed 2025-11-12 | -$513.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$221.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.22M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$1.00M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $1.65M 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |